54
ВЕСТНИК РАМН /2015/ № 1
17. Muller H., Johne R. Rotaviruses: diversity and zoonotic poten-
tial — a brief review. Berl. Munch. Tierarztl. Wochenschr. 2007; 120:
108–112.
18. Vesikari T., Kapikian A.Z., Delem A., Zissis G. A comparative trial
of rhesus monkey (RRV–1) and bovine (RIT 4237) oral rota-
virus vaccines in young children. J. Infect. Dis. 1986; 153: 832–
839.
19. WHO. Global rotavirus information and surveillance bulletin.
2010. Vol. 4.
20. O’Ryan M. The ever changing landscape of rotavirus serotypes.
Pediatr. Infect. Dis. J. 2009; 28 (3; Suppl.): 60–62.
21. Matthijnssens J., Heylen E., Zeller M., Rahman M., Lemey P.,
Van Ranst M. Phylodynamic analyses of rotavirus genotypes G9 and
G12 underscore their potential for swift global spread. Mol. Biol. Evol.
2010; 27: 2431–2436.
22. Seheri M., Nemarude L., Peenze I., Netshifhefhe L,. Nyaga M.M.,
Ngobeni H.G., Maphalala G., Maake L.L., Steele A.D., Mwenda
J.M., Mphahlele J.M. Update of rotavirus strains circulating in Afri-
ca from 2007 through 2011. Pediatr. Infect. Dis. J. 2014; 33 (Suppl. 1):
76–84.
23. Mijatovic-Rustempasic S., Teel E.N., Kerin T.K., Hull J.J., Roy S.,
Weinberg G.A., Payne D.C., Parashar U.D., Gentsch J.R.,
Bowen M.D. Genetic analysis of G12P[8] rotaviruses detected in
the largest U.S. G12 genotype outbreak on record. Infect. Genet.
Evol. 2014; 21: 214–219.
24. Desselberger U., Huppertz H.I. Immune responses to rotavirus
infection and vaccination and associated correlates of protection.
J. Infect. Dis. 2011; 203: 188–195.
25. Velazquez F.R., Matson D.O., Calva J.J., Morrow A.L., Glass R.I.,
Pickering L.K., Ruiz-Palacios G.M. Rotavirus infections in infants
as protection against subsequent infections. N. Engl. J. Med. 1996;
335: 1022–1028.
26. White L.J., Buttery J., Cooper B., Nokes D.J., Medley G.F. Rota-
virus within day care centres in Oxfordshire, UK: Characterization
of partial immunity. J. R. Soc. Interface. 2008; 5: 1481–1490.
27. Chiba S., Yokoyama T., Nakata S., Morita Y., Urasawa T., Taniguchi K.,
Urasawa S., Nakao T. Protective effect of naturally acquired
homotypic heterotypic rotavirus antibodies. Lancet. 1986; 2: 417–
421.
27. Jaimes M.C., Rojas O.L., Kunkel E.J., Lazarus N.H., Soler D.,
Butcher E.C., Bass D., Angel J., Franco M.A., Greenberg H.B.
Maturation trafficking markers on rotavirus specific B cells dur-
ing acute infection and convalescence in children. J. Virol. 2004;
78: 10967–10976.
28. Coulson B.S., Grimwood K., Hudson I.L., Barnes G.L.,
Bishop R.F. Role of coproantibody in clinical protection of chil-
dren during reinfection with rotavirus. J. Clin. Microbiol. 1992;
30: 1678–1684.
29. Soares-Weiser K., MacLehose H., Bergman H., Ben-Aharon I.,
Nagpal S., Goldberg E., Pitan F., Cunliffe N. Vaccines for prevent-
ing rotavirus diarrhoea: vaccines in use. Cochr. Database Syst. Rev.
2012; 14: 11.
30. Vesikari T. Rotavirus vaccination: a concise review. Clin. Microbiol.
Infect. 2012; 18 (Suppl. 5): 57–63.
31. Tate J.E., Parashar U.D. Rotavirus vaccines in routine use. Clin.
Infect. Dis. 2014; 59: 1291–1301.
32. Bhandari N., Rongsen-Chandola T., Bavdekar A., John J., Antony
K., Taneja S., Goyal N., Kawade A., Kang G., Rathore S.S.,
Juvekar S., Muliyil J., Arya A., Shaikh H., Abraham V., Vrati S.,
Proschan M., Kohberger R. Thiry G., Glass R., Greenberg H.B.,
Curlin G., Mohan K., Harshavardhan G.V., Prasad S., Rao T.S.,
Boslego J., Bhan M.K. Efficacy of a monovalent human-bovine
(116E) rotavirus vaccine in Indian infants: a randomised, double
blind, placebo-controlled trial. Lancet. 2014; 383: 2136–2143.
33. Groome M.J., Page N., Cortese M.M., Moyes J., Zar H.J.,
Kapongo C.N., Mulligan C., Diedericks R., Cohen C.,
Fleming J.A., Seheri M., Mphahlele J., Walaza S., Kahn K.,
Chhagan M., Steele A.D., Parashar U.D., Zell E.R.,
Madhi S.A. Effectiveness of monovalent human rotavirus vaccine
against admission to hospital for acute rotavirus diarrhoea in South
African children: a case control study. Lancet Inf. Dis. 2014; 14 (11):
1096–1104.
34. Madhi S.A., Cunliffe N.A., Steele D. Witte D., Kirsten M., Louw C.,
Ngwira B., Victor J.C., Gillard P.H., Cheuvart B.B., Han H.H.,
Neuzil K.M. Effect of human rotavirus vaccine on severe diarrhea in
African infants. N. Engl. J. Med. 2010; 362: 289–298.
35. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D.,
Feikin D.R., Binka F.N., Steele A.D., Laserson K.F., Ansah N.A.,
Levine M.M., Lewis K., Coia M.L., Attah-Poku M., Ojwando J., Riv-
ers S.B., Victor J.C., Nyambane G., Hodgson A., Schödel F., Ciar-
let M., Neuzil K.M. Efficacy of pentavalent rotavirus vaccine against
severe rotavirus gastroenteritis in infants in developing countries in
sub-Saharan Africa: a randomised, doubleblind, placebo-controlled
trial. Lancet. 2010; 376: 606–614.
36. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J.,
Podder G., Vu D.T., Le T.P., Luby S.P., Le H.T., Coia M.L., Lewis
K., Rivers S.B., Sack D.A., Schödel F., Steele A.D., Neuzil K.M.,
Ciarlet M. Efficacy of pentavalent rotavirus vaccine against severe
rotavirus gastroenteritis in infants in developing countries in Asia:
a randomised, double-blind, placebo-controlled trial. Lancet. 2010;
376: 615–623.
37. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C.,
Cohen R., Meurice F., Han H.H., Damaso S., Bouckenooghe A.
Efficacy of human rotavirus vaccine against rotavirus gastroen-
teritis during the first 2 years of life in European infants: ran-
domised, double blind controlled study. Lancet. 2007; 370: 1757–
1763.
38. Vesikari T., Karvonen A., Ferrante S.A., Ciarlet M. Efficacy of the
pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to
3 years of age: the Finnish Extension Study. Eur. J. Pediatr. 2010;
169: 1379–1386.
39. Carvalho-Costa F.A., Volotao E.M., de Assis RMS et al. Labora-
tory based rotavirus surveillance during the introduction of a vac-
cination program, Brazil, 2005–2009. Pediatr. Infect. Dis. J. 2011;
30: 35–41.
40. Glass R.I., Parashar U.D., Bresee J.S., Turcios R., Fischer T.K.,
Widdowson M.A., Jiang B., Gentsch J.R. Rotavirus vaccines:
current prospects and future challenges. Lancet. 2006; 368: 323–
332.
41. Meeting of the Strategic Advisory Group of Experts on immuniza-
tion, October 2009 — conclusions and recommendations. Wkly
Epidemiol. Rec. 2009; 84: 517–532.
42. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B.,
Jumaan A.O., Okoro C.A., Zanardi L.R., Setia S., Fair E., LeB-
aron C.W., Wharton M., Livengood J.R. Intussusception among
infants given an oral rotavirus vaccine. N. Eng.l J. Med. 2001; 344:
561–572.
43. Simonsen L., Vlboud C., Elixhauser A., Taylor R.J., Kapikian A.Z.
More on Rota Shield and intussusception: the role of age at the time
of vaccination. J. Infect. Dis. 2005; 192 (Suppl. 1): 36–43.
44. Yih W.K., Lieu T.A., Kulldorff M., Martin D,. McMahill-Walra-
ven C.N., Platt R., Selvam N., Selvan M., Lee G.M., Nguyen M.
Intussusception risk after rotavirus vaccination in U.S. infants. N. Engl.
J. Med. 2014; 370: 503–512.
45. Weintraub E.S., Baggs J., Duffy J., Vellozzi C., Belongia E.A., Irving S.,
Klein N.P., Glanz J.M., Jacobsen S.J., Naleway A., Jackson L.A.,
DeStefano F. Risk of intussusception after monovalent rotavirus
vaccination. N. Engl. J. Med. 2014; 370: 513–519.
46. Rotavirus vaccines: WHO position paper —January 2013. Wkly Epi-
demiol. Rec. 2013; 88: 49–64.
47. Programmes WHO. URL:www.who.int/vaccine_safety/commit-
tee/topics/rotavirus/rotavac/Jun_2014/en/. (available: 11.10.2014).